novartis-infigratinib
Preclinical
Novartisnovartis-infigratinib is one of 7 therapeutic programs targeting Bile Duct Cancer. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
7 competitors in Bile Duct Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerApproved
Photofrin
PPinnacle Biologics Inc.
Approved
Ixempra
RR-Pharm
Approved
Photosensitizer
UUniversity of Leipzig
Phase 3
Tecentriq
RochePreclinical
Fotivda
AAVEO Pharmaceuticals, Inc.
Preclinical
novartis-infigratinib
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for novartis-infigratinib. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company